News

GlaxoSmithKline (GSK) announced that it has filed a New Drug Application with Japan’s regulatory health agency requesting that belimumab — widely known under the brand name Benlysta — be approved to treat adults with active, autoantibody-positive, systemic lupus erythematosus (SLE, lupus) who do not respond to standard therapy. GSK seeks approval…

A new research study exploring the effects of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) on hearing, cognition, and language is calling for volunteers. The study, to be conducted at the Department of Communication Sciences and Disorders of East Stroudsburg University, aims to better understand both these…

The immune factor interferon-lambda may be a key driver of lupus nephritis, according to a recent study that showed persistently high levels of the factor were linked to a poor response to treatment. The study, “Interferon (IFN)-λ is a potential mediator in lupus nephritis,” was published in the journal …

A large-scale retrospective study found that patients with systemic lupus erythematosus (SLE) may be twice as likely to develop dementia as others of similar age and sex, a finding that may help to improve their care. The study, “Increased Risk of Dementia in Patients with Systemic Lupus Erythematosus: A Nationwide…

Eye damage, also referred to as retinopathy, caused by systemic lupus erythematosus may be a sign of more severe disease, as patients with lupus retinopathy have kidney damage more often than patients without eye disease. As lupus retinopathy is suggested to reflect damage to small blood vessels throughout the body,…

Those who develop lupus as youngsters have more severe symptoms and a higher chance of an earlier death, according to a new study. The study in the British journal Lupus suggests that since patients with juvenile-onset systemic lupus erythematosus (JSLE) constitute a high-risk group, doctors need to devote extra attention…